Retatrutide – ushering in the era of “triple receptor agonists” for weight loss?
Studies showed that, with weekly administration, at week 24, overweight/obese non-diabetic subjects in the retatrutide 12mg group experienced a mean weight loss of 18.7 kg (17.5%); in the secondary endpoint, the retatrutide 12mg group achieved a mean weight loss of 26.2 kg (24.2%) at the end of week 48 treatment.




















